| Patient | Evel Knievel |
|---|---|
| Date of birth | 1968-10-17 |
| Identifiers | MRN HR-RB001-SYN; SSN (made up) 000-01-4927 |
| Document date | 2026-11-01 |
| Author | Dale Rasmussen, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New patient: chronic pain from old fractures, diabetes, and raised liver tests with low platelets on today's tests: hepatitis C and liver work-up, NSAIDs stopped, alcohol counseling, and hepatology review booked. Concerns: Pain in the back, hips and knees every day from old fractures, worse in the morning and after travel; ibuprofen three times a day for years; Tired for months; noticed small red spots on his chest and wonders whether the old transfusions or his drinking have hurt his liver; He wants to keep walking and playing golf and does not want to depend on strong pain pills; Two falls in the past year; he worries about breaking another bone. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals | One tablet twice daily with breakfast and supper | Oral route | 2021-03-01 | active | S |
| Ibuprofen 800 mg oral tablet, one tablet three times a day for joint and back pain | One tablet three times a day | Oral route | 2024-06-01 to 2026-01-12 | completed | S |
| Omeprazole 20 mg delayed-release oral capsule, one capsule daily for indigestion from ibuprofen | One capsule daily before breakfast | Oral route | 2024-06-01 to 2026-01-12 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth up to twice a day as needed for pain, no more than 2 g a day | Two tablets up to twice a day as needed; no more than 2 g a day | Oral route | 2026-01-12 | active | S |
| Diclofenac sodium 1% topical gel, 4 g to the knees up to four times a day | 4 g to each knee up to four times a day | Topical route | 2026-01-12 | active | S |
| Carvedilol 6.25 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-01-26 to 2026-02-23 | completed | S |
| Carvedilol 12.5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-02-23 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-01-26 | active | S |
| Sofosbuvir 400 mg and velpatasvir 100 mg oral tablet, one tablet daily for 12 weeks | One tablet daily for 12 weeks | Oral route | 2026-02-23 to 2026-05-17 | completed | S |
| Cholecalciferol (vitamin D3) 50 mcg (2000 units) oral capsule, one capsule daily | One capsule daily | Oral route | 2026-02-23 | active | S |
| Zoledronic acid 5 mg in 100 mL, intravenous infusion over at least 15 minutes, once a year | Once a year | Intravenous route | 2026-06-01 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Ultrasound of the abdomen with Doppler: nodular liver surface and coarse echotexture; no focal liver lesion; spleen 14.2 cm; portal vein patent with forward flow; no ascites; gallbladder normal | 2026-01-19 to 2026-01-19 | completed | S |
| Transient elastography (FibroScan) at the hepatology visit: median liver stiffness 26.8 kPa (interquartile range under 30% of the median), controlled attenuation parameter 248 dB/m | 2026-01-26 to 2026-01-26 | completed | S |
| Outpatient physical therapy assessment: limited hip and knee range from old fractures, slow gait, Timed Up and Go 13 seconds, poor single-leg balance; aquatic therapy twice a week and a home exercise program; cane for long distances | 2026-02-02 to 2026-02-02 | completed | S |
| Dual-energy X-ray absorptiometry: femoral neck T-score -2.6, total hip -2.2, lumbar spine -1.9 (read with caution because of old fractures and degenerative change); 10-year FRAX risk of major osteoporotic fracture 14% and hip fracture 4.1% | 2026-03-09 to 2026-03-09 | completed | S |
| Surveillance ultrasound of the liver six months after the baseline scan: nodular liver, no focal lesion; spleen 13.8 cm; no ascites (LI-RADS US-1, negative) | 2026-08-10 to 2026-08-10 | completed | S |
| Advance care planning conversation, about 20 minutes | 2026-09-21 to 2026-09-21 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2026-01-26 | Hepatitis A vaccine, adult, dose 1 of 2 | completed | S |
| 2026-01-26 | Hepatitis B vaccine (recombinant, CpG adjuvanted), dose 1 of 2 | completed | S |
| 2026-02-23 | Hepatitis B vaccine (recombinant, CpG adjuvanted), dose 2 of 2 | completed | S |
| 2026-08-17 | Hepatitis A vaccine, adult, dose 2 of 2 | completed | S |
| 2026-09-21 | Influenza vaccine, inactivated, trivalent, preservative free, this season | completed | S |
| 2026-09-21 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 2026-09-21 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
| 2026-09-21 | Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1968 | Crash after jumping the fountains at Caesars Palace, Las Vegas, with a long hospital stay (reported as a month in a coma) | D (CLM-0002) |
| September 8, 1974 | Failed rocket-cycle jump of the Snake River Canyon, Idaho | D (CLM-0003) |
| 1975 | Broken pelvis in the crash landing of a jump over 13 buses at Wembley Stadium, London; Guinness World Records counts 433 fractures by the end of that year (disputed; his obituaries say nearly 40 broken bones in his career) | D (CLM-0003, CLM-0004) |
| 1976 | Concussion and two broken arms in a jump attempt in Chicago; retired from major jumps | D (CLM-0003) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| Pain in the back, hips and knees every day from old fractures, worse in the morning and after travel; ibuprofen three times a day for years | active | S |
| Tired for months; noticed small red spots on his chest and wonders whether the old transfusions or his drinking have hurt his liver | active | S |
| He wants to keep walking and playing golf and does not want to depend on strong pain pills | active | S |
| Two falls in the past year; he worries about breaking another bone | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 14.4 on 2026-08-17; Leukocytes [#/volume] in Blood by Automated count 5.2 on 2026-08-17; Platelets [#/volume] in Blood by Automated count 134 on 2026-08-17; Sodium [Moles/volume] in Serum or Plasma 137 on 2026-01-12; Potassium [Moles/volume] in Serum or Plasma 4.3 on 2026-01-12; Creatinine [Mass/volume] in Serum or Plasma 0.88 on 2026-08-17; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 100 on 2026-08-17; Glucose [Mass/volume] in Serum or Plasma 112 on 2026-08-17; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 on 2026-08-17; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 26 on 2026-08-17; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 92 on 2026-08-17; Bilirubin.total [Mass/volume] in Serum or Plasma 0.8 on 2026-08-17; Albumin [Mass/volume] in Serum or Plasma 4 on 2026-08-17; INR in Platelet poor plasma by Coagulation assay 1 on 2026-08-17; Hemoglobin A1c/Hemoglobin.total in Blood 6.3 on 2026-08-17; Cholesterol [Mass/volume] in Serum or Plasma 148 on 2026-09-21; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 68 on 2026-09-21; Cholesterol in HDL [Mass/volume] in Serum or Plasma 42 on 2026-09-21; Triglyceride [Mass/volume] in Serum or Plasma 140 on 2026-09-21; Albumin/Creatinine [Mass Ratio] in Urine 18 on 2026-01-12; Total score [AUDIT-C] 0 on 2026-08-17; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-09-21; Pain severity - 0-10 verbal numeric rating [Score] - Reported 4 on 2026-08-17; Liver stiffness by US.transient elastography 26.8 on 2026-01-26; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 2026-08-17; Calcium [Mass/volume] in Serum or Plasma 9.3 on 2026-05-18; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 34 on 2026-05-18; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 388 on 2026-02-23; Thyrotropin [Units/volume] in Serum or Plasma 2.1 on 2026-02-23; Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection 0 on 2026-08-17; Glucose management indicator 6.8 on 2026-08-17; Parathyrin.intact [Mass/volume] in Serum or Plasma 48 on 2026-05-18; Testosterone [Mass/volume] in Serum or Plasma 455 on 2026-05-18; Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma 3.4 on 2026-08-17; Prostate specific Ag [Mass/volume] in Serum or Plasma 1.3 on 2026-09-21 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Raised transaminases (ALT 88, AST 96 U/L) and low platelets (118) on today's tests, with spider angiomas and palmar erythema, in a man of 57 who received many blood transfusions after crashes before 1992 and drinks most evenings: chronic liver disease, most likely hepatitis C, must be excluded. Hepatitis C antibody with reflex RNA, hepatitis A and B serology, HIV, liver ultrasound and hepatology review ordered | resolved | confirmed | R74.01 | S — Synthetic presenting problem; no symptom or result of his real illness was made public. Superseded at the hepatology consultation. |
| Chronic hepatitis C, genotype 1a, treatment-naive, HCV RNA 2.35 million IU/mL, likely acquired through blood transfusions after crashes; synthetic modern detail linked to his publicly reported transfusion-acquired hepatitis C | resolved | confirmed | B18.2 | S — Synthetic genotype, viral load and timing; his hepatitis C and its likely transfusion source are documented (D). |
| Compensated cirrhosis from hepatitis C, with alcohol as a cofactor: liver stiffness 26.8 kPa, FIB-4 4.94, nodular liver and a 14.2 cm spleen on ultrasound, platelets 118; Child-Pugh A5, MELD-Na 8; no ascites, encephalopathy, jaundice or bleeding | active | confirmed | K74.69 | S — Synthetic stage of liver disease linked to his documented hepatitis C and later liver transplant. |
| Clinically significant portal hypertension in compensated cirrhosis (liver stiffness 25 kPa or more), treated with carvedilol without screening endoscopy (Baveno VII) | active | confirmed | K76.6 | S — Synthetic finding at the hepatology consultation. |
| Type 2 diabetes on metformin, A1c 7.4% | active | confirmed | E11.65 | S — Synthetic; diabetes is documented only in his last years (D), and placing it at 57 is a synthetic choice. |
| Chronic pain in the back, hips, pelvis and knees after dozens of fractures from stunt crashes, including a broken pelvis; ibuprofen stopped, and managed without oral NSAIDs or opioids | active | confirmed | G89.29 | S — Synthetic pain at the index age, anchored to his documented fractures and the pain of his later years. |
| Osteoporosis in a man with cirrhosis, prior heavy alcohol use and dozens of old fractures: femoral neck T-score -2.6, lumbar spine -1.9 | active | confirmed | M81.8 | S — Synthetic bone density result. |
| Vitamin D deficiency (25-hydroxyvitamin D 17 ng/mL) | resolved | confirmed | E55.9 | S — Synthetic finding before the bone density scan. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-01-12 | Hemoglobin [Mass/volume] in Blood | 13.9 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 2026-01-12 | Leukocytes [#/volume] in Blood by Automated count | 4.6 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-01-12 | Platelets [#/volume] in Blood by Automated count | 118 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 2026-01-12 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-01-12 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-01-12 | Creatinine [Mass/volume] in Serum or Plasma | 0.92 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-01-12 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 97 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-01-12 | Glucose [Mass/volume] in Serum or Plasma | 162 | mg/dL | 70-99 mg/dL | High | S |
| 2026-01-12 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 88 | U/L | 7-55 U/L | High | S |
| 2026-01-12 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 96 | U/L | 8-48 U/L | High | S |
| 2026-01-12 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 104 | U/L | 40-129 U/L | Normal | S |
| 2026-01-12 | Bilirubin.total [Mass/volume] in Serum or Plasma | 1.1 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-01-12 | Albumin [Mass/volume] in Serum or Plasma | 3.6 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-01-12 | INR in Platelet poor plasma by Coagulation assay | 1.1 | {INR} | 0.9-1.1 | Normal | S |
| 2026-01-12 | Hemoglobin A1c/Hemoglobin.total in Blood | 7.4 | % | Below 5.7% is normal; individual goal below 7%; may read falsely low in cirrhosis | High | S |
| 2026-01-12 | Cholesterol [Mass/volume] in Serum or Plasma | 186 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-01-12 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 112 | mg/dL | Goal below 100 mg/dL in diabetes, below 70 if higher risk | High | S |
| 2026-01-12 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 38 | mg/dL | >=40 mg/dL | Low | S |
| 2026-01-12 | Triglyceride [Mass/volume] in Serum or Plasma | 178 | mg/dL | <=149 mg/dL | High | S |
| 2026-01-12 | Albumin/Creatinine [Mass Ratio] in Urine | 18 | mg/g | <=29 mg/g | Normal | S |
| 2026-01-12 | Total score [AUDIT-C] | 7 | {score} | S | ||
| 2026-01-12 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-01-12 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 7 | {score} | S | ||
| 2026-01-26 | Liver stiffness by US.transient elastography | 26.8 | kPa | Below 7 kPa normal; above 12.5 kPa cirrhosis; 25 kPa or more clinically significant portal hypertension | High | S |
| 2026-01-26 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 2026-01-26 | Total score [AUDIT-C] | 4 | {score} | S | ||
| 2026-01-26 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 6 | {score} | S | ||
| 2026-02-23 | Hemoglobin [Mass/volume] in Blood | 14 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 2026-02-23 | Leukocytes [#/volume] in Blood by Automated count | 4.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-02-23 | Platelets [#/volume] in Blood by Automated count | 121 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 2026-02-23 | Creatinine [Mass/volume] in Serum or Plasma | 0.9 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-02-23 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 100 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-02-23 | Glucose [Mass/volume] in Serum or Plasma | 141 | mg/dL | 70-99 mg/dL | High | S |
| 2026-02-23 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 81 | U/L | 7-55 U/L | High | S |
| 2026-02-23 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 90 | U/L | 8-48 U/L | High | S |
| 2026-02-23 | Bilirubin.total [Mass/volume] in Serum or Plasma | 1 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-02-23 | Albumin [Mass/volume] in Serum or Plasma | 3.7 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-02-23 | Calcium [Mass/volume] in Serum or Plasma | 9.1 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-02-23 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 17 | ng/mL | 30-100 ng/mL | Low | S |
| 2026-02-23 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 388 | pg/mL | 232-1245 pg/mL | Normal | S |
| 2026-02-23 | Thyrotropin [Units/volume] in Serum or Plasma | 2.1 | m[IU]/L | 0.4-4.5 mIU/L | Normal | S |
| 2026-02-23 | Total score [AUDIT-C] | 1 | {score} | S | ||
| 2026-02-23 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 2026-02-23 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 5 | {score} | S | ||
| 2026-05-18 | Hemoglobin [Mass/volume] in Blood | 14.2 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 2026-05-18 | Leukocytes [#/volume] in Blood by Automated count | 5 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-05-18 | Platelets [#/volume] in Blood by Automated count | 129 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 2026-05-18 | Creatinine [Mass/volume] in Serum or Plasma | 0.89 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-05-18 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 100 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-05-18 | Glucose [Mass/volume] in Serum or Plasma | 118 | mg/dL | 70-99 mg/dL | High | S |
| 2026-05-18 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 7-55 U/L | Normal | S |
| 2026-05-18 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 29 | U/L | 8-48 U/L | Normal | S |
| 2026-05-18 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-05-18 | Albumin [Mass/volume] in Serum or Plasma | 3.9 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-05-18 | Calcium [Mass/volume] in Serum or Plasma | 9.3 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-05-18 | Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection | 0 | [IU]/mL | Not detected is reported as 0; lower limit of quantification 15 IU/mL | Normal | S |
| 2026-05-18 | Hemoglobin A1c/Hemoglobin.total in Blood | 6.4 | % | Below 5.7% is normal; individual goal below 7%; may read falsely low in cirrhosis | High | S |
| 2026-05-18 | Glucose management indicator | 6.9 | % | Individual goal below 7% | Normal | S |
| 2026-05-18 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 34 | ng/mL | 30-100 ng/mL | Normal | S |
| 2026-05-18 | Parathyrin.intact [Mass/volume] in Serum or Plasma | 48 | pg/mL | 15-65 pg/mL | Normal | S |
| 2026-05-18 | Testosterone [Mass/volume] in Serum or Plasma | 455 | ng/dL | 264-916 ng/dL | Normal | S |
| 2026-05-18 | Total score [AUDIT-C] | 0 | {score} | S | ||
| 2026-05-18 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 2026-05-18 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 4 | {score} | S | ||
| 2026-08-17 | Hemoglobin [Mass/volume] in Blood | 14.4 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 2026-08-17 | Leukocytes [#/volume] in Blood by Automated count | 5.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-08-17 | Platelets [#/volume] in Blood by Automated count | 134 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 2026-08-17 | Creatinine [Mass/volume] in Serum or Plasma | 0.88 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-08-17 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 100 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-08-17 | Glucose [Mass/volume] in Serum or Plasma | 112 | mg/dL | 70-99 mg/dL | High | S |
| 2026-08-17 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-55 U/L | Normal | S |
| 2026-08-17 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 8-48 U/L | Normal | S |
| 2026-08-17 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 92 | U/L | 40-129 U/L | Normal | S |
| 2026-08-17 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-08-17 | Albumin [Mass/volume] in Serum or Plasma | 4 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-08-17 | INR in Platelet poor plasma by Coagulation assay | 1 | {INR} | 0.9-1.1 | Normal | S |
| 2026-08-17 | Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection | 0 | [IU]/mL | Not detected is reported as 0; lower limit of quantification 15 IU/mL | Normal | S |
| 2026-08-17 | Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma | 3.4 | ng/mL | <=8.3 ng/mL | Normal | S |
| 2026-08-17 | Hemoglobin A1c/Hemoglobin.total in Blood | 6.3 | % | Below 5.7% is normal; individual goal below 7%; may read falsely low in cirrhosis | High | S |
| 2026-08-17 | Glucose management indicator | 6.8 | % | Individual goal below 7% | Normal | S |
| 2026-08-17 | Total score [AUDIT-C] | 0 | {score} | S | ||
| 2026-08-17 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 2026-08-17 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 4 | {score} | S | ||
| 2026-09-21 | Cholesterol [Mass/volume] in Serum or Plasma | 148 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-09-21 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 68 | mg/dL | Goal below 100 mg/dL in diabetes, below 70 if higher risk | Normal | S |
| 2026-09-21 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 42 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-09-21 | Triglyceride [Mass/volume] in Serum or Plasma | 140 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-09-21 | Prostate specific Ag [Mass/volume] in Serum or Plasma | 1.3 | ng/mL | <=4 ng/mL | Normal | S |
| 2026-09-21 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-01-12 | Body height | 178 | cm | S |
| 2026-01-12 | Body weight | 86 | kg | S |
| 2026-01-12 | Body mass index (BMI) [Ratio] | 27.1 | kg/m2 | S |
| 2026-01-12 | Systolic blood pressure | 138 | mm[Hg] | S |
| 2026-01-12 | Diastolic blood pressure | 84 | mm[Hg] | S |
| 2026-01-12 | Heart rate | 80 | /min | S |
| 2026-01-12 | Respiratory rate | 14 | /min | S |
| 2026-01-12 | Body temperature | 36.6 | Cel | S |
| 2026-01-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-01-26 | Body height | 178 | cm | S |
| 2026-01-26 | Body weight | 85.6 | kg | S |
| 2026-01-26 | Body mass index (BMI) [Ratio] | 27 | kg/m2 | S |
| 2026-01-26 | Systolic blood pressure | 136 | mm[Hg] | S |
| 2026-01-26 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2026-01-26 | Heart rate | 78 | /min | S |
| 2026-01-26 | Respiratory rate | 14 | /min | S |
| 2026-01-26 | Body temperature | 36.7 | Cel | S |
| 2026-01-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-02-23 | Body height | 178 | cm | S |
| 2026-02-23 | Body weight | 84.8 | kg | S |
| 2026-02-23 | Body mass index (BMI) [Ratio] | 26.8 | kg/m2 | S |
| 2026-02-23 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-02-23 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-02-23 | Heart rate | 68 | /min | S |
| 2026-02-23 | Respiratory rate | 14 | /min | S |
| 2026-02-23 | Body temperature | 36.6 | Cel | S |
| 2026-02-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-05-18 | Body height | 178 | cm | S |
| 2026-05-18 | Body weight | 83.2 | kg | S |
| 2026-05-18 | Body mass index (BMI) [Ratio] | 26.3 | kg/m2 | S |
| 2026-05-18 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-05-18 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-05-18 | Heart rate | 62 | /min | S |
| 2026-05-18 | Respiratory rate | 14 | /min | S |
| 2026-05-18 | Body temperature | 36.5 | Cel | S |
| 2026-05-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-08-17 | Body height | 178 | cm | S |
| 2026-08-17 | Body weight | 82.6 | kg | S |
| 2026-08-17 | Body mass index (BMI) [Ratio] | 26.1 | kg/m2 | S |
| 2026-08-17 | Systolic blood pressure | 120 | mm[Hg] | S |
| 2026-08-17 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-08-17 | Heart rate | 60 | /min | S |
| 2026-08-17 | Respiratory rate | 14 | /min | S |
| 2026-08-17 | Body temperature | 36.6 | Cel | S |
| 2026-08-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-09-21 | Body height | 178 | cm | S |
| 2026-09-21 | Body weight | 82.4 | kg | S |
| 2026-09-21 | Body mass index (BMI) [Ratio] | 26 | kg/m2 | S |
| 2026-09-21 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-09-21 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-09-21 | Heart rate | 62 | /min | S |
| 2026-09-21 | Respiratory rate | 14 | /min | S |
| 2026-09-21 | Body temperature | 36.6 | Cel | S |
| 2026-09-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-01-12 | New patient: chronic pain from old fractures, diabetes, and raised liver tests with low platelets on today's tests: hepatitis C and liver work-up, NSAIDs stopped, alcohol counseling, and hepatology review booked | finished | S |
| 2026-01-26 | Hepatitis C confirmed with compensated cirrhosis: elastography, hepatology consultation, carvedilol for portal hypertension, statin, vaccines, and the antiviral plan | finished | S |
| 2026-02-23 | Day 1 of sofosbuvir-velpatasvir: drug interaction check, carvedilol titration, glucose monitoring, vitamin D, and the bone density plan | finished | S |
| 2026-05-18 | End of 12 weeks of antiviral treatment: liver tests, glucose monitoring in cirrhosis, osteoporosis, pain, and abstinence | finished | S |
| 2026-08-17 | Cure confirmed (SVR12): six-month liver cancer surveillance, cirrhosis care after cure, and transplant criteria reviewed | finished | S |
| 2026-09-21 | Periodic adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Hepatology consultation within three weeks to confirm and stage chronic liver disease and plan antiviral treatment if hepatitis C is confirmed | completed | GL-AASLD-HCV-2026, GL-AASLD-HCC-2023 | S |
| Liver work-up for raised transaminases and low platelets: hepatitis C antibody with reflex RNA, hepatitis B surface antigen, core antibody and surface antibody, hepatitis A IgG, HIV, INR, ultrasound of the abdomen, and FIB-4 from today's tests | completed | GL-AASLD-HCV-2026, GL-USPSTF-HCV-2020 | S |
| Pain care safe in liver disease: stop ibuprofen and omeprazole; acetaminophen up to 2 g a day; topical diclofenac for the knees; no opioids; physical and aquatic therapy; heat, pacing and sleep routines; pain coping skills | completed | GL-RAKOSKI-2018, GL-CDC-OPIOID-2022 | S |
| Alcohol: brief counseling toward stopping completely, because alcohol speeds liver scarring; follow-up AUDIT-C at each visit; counseling or medicine for alcohol use offered if he cannot stop | completed | GL-USPSTF-ALC-2018, GL-AASLD-ALD-2019 | S |
| Sofosbuvir-velpatasvir one tablet daily for 12 weeks under the AASLD-IDSA simplified pathway for compensated cirrhosis, after hepatitis B testing and a drug interaction check (no proton pump inhibitor; watch for muscle pain on atorvastatin); glucose monitoring for hypoglycemia; HCV RNA and liver tests 12 or more weeks after the last dose | completed | GL-AASLD-HCV-2026, GL-AASLD-HCV-MON, GL-EPCLUSA-LABEL | S |
| Carvedilol for clinically significant portal hypertension (liver stiffness 25 kPa or more), started at 6.25 mg and raised to 12.5 mg daily if blood pressure allows; no screening endoscopy while he takes it; liver stiffness and platelets rechecked a year after cure | completed | GL-BAVENO-VII-2022, GL-AASLD-PH-2024 | S |
| Liver cancer surveillance by ultrasound with alpha-fetoprotein every six months, continuing after cure because cirrhosis remains | completed | GL-AASLD-HCC-2023, GL-AASLD-HCV-2026 | S |
| Vaccines for chronic liver disease: hepatitis A (two doses) and hepatitis B (two doses), then influenza, pneumococcal and zoster vaccines at the preventive visit | completed | GL-CDC-IMZ-2026, GL-AASLD-HCV-2026 | S |
| Teaching on decompensation (swelling of the abdomen or legs, black stools or vomiting blood, confusion, yellow eyes) with same-day contact; transplant referral only if decompensation occurs or the MELD-Na reaches 15 | completed | GL-AASLD-ASCITES-2021, GL-AASLD-PH-2024 | S |
| Diabetes care adapted to cirrhosis: metformin continued while kidney function is normal and he does not drink; continuous glucose monitoring because the A1c can read falsely low; moderate-intensity statin; yearly eye and foot examinations and urine albumin | completed | GL-ADA-4-2026, GL-ADA-6-2026, GL-CMID-2026 | S |
| Falls and fractures: physical therapy and a home safety review; vitamin D; bone density scan, since cirrhosis, alcohol and many old fractures raise the risk of osteoporosis | completed | GL-ENDO-OSTEO-MEN-2012, GL-CMID-2026 | S |
| Zoledronic acid 5 mg intravenously once a year, after vitamin D repletion and a normal calcium, rather than an oral bisphosphonate because of portal hypertension; dental review first; bone density again in two years | completed | GL-ENDO-OSTEO-MEN-2012, GL-CMID-2026 | S |
| Depression and distress screening at each visit, and plain explanations with written information | completed | GL-USPSTF-DEP-2023, GL-CMID-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Hepatitis C confirmed or excluded and liver disease staged within three weeks | 2026-01-26 | completed | Chronic hepatitis C, genotype 1a, with compensated cirrhosis staged at two weeks | S |
| Cure of hepatitis C: HCV RNA not detected 12 or more weeks after treatment | 2026-08-17 | completed | HCV RNA not detected 13 weeks after a 12-week course | S |
| No decompensation (ascites, variceal bleeding, encephalopathy or jaundice); Child-Pugh A and MELD-Na below 15 | 2026-08-17 | completed | No decompensation; Child-Pugh A5; MELD-Na 6 after cure | S |
| No alcohol | 2026-08-17 | completed | No alcohol since the start of antiviral treatment; AUDIT-C 0 | S |
| Pain 4 of 10 or less, walking 30 minutes, with no oral NSAIDs or opioids | 2026-08-17 | completed | Pain 4 of 10; walking 30 minutes in the pool and on flat ground; no NSAIDs or opioids | S |
| Glucose management indicator below 7% without hypoglycemia | 2026-08-17 | completed | Glucose management indicator 6.8%; no hypoglycemia | S |
| Vitamin D replete and osteoporosis treatment started; no falls with injury | 2026-08-17 | completed | Vitamin D 34 ng/mL; zoledronic acid given; no further falls | S |